Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perilla leaf extract (PLE) is a botanical extract derived from *Perilla frutescens* (L.) Britt., a traditional medicinal plant known for its antioxidant and anti-inflammatory properties. PLE has been studied for its potential to treat respiratory diseases, specifically chronic obstructive pulmonary disease (COPD). Its therapeutic effect is attributed to the suppression of the TLR4/Syk/PKC/NF-κB p65 signaling pathway, which results in reduced infiltration of inflammatory cells like neutrophils and macrophages into lung tissue. Additionally, PLE inhibits the production of key inflammatory mediators, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-17A (IL-17A), thereby ameliorating airway inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on perilla leaf extract.